GH ResearchNASDAQ: GHRS
GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland, developing novel mebufotenin (5-MeO-DMT) therapeutics for treatment-resistant depression, bipolar II disorder, and postpartum depression. Its lead asset GH001 — an inhaled mebufotenin formulation — met the primary endpoint of its Phase 2b TRD trial in February 2025 with striking results: -15.5 point MADRS reduction vs placebo (p<0.0001) and 57.7% remission vs 0%. With a single-day dosing paradigm requiring no structured psychotherapy, GH001 is positioned as a differentiated asset; Phase 3 global initiation is planned for 2026 following FDA clinical hold lift. GH002 (IV mebufotenin) completed Phase 1 in healthy volunteers.
Drug Pipeline
4GH001
5-MeO-DMTTreatment-resistant depression (TRD). Inhaled mebufotenin. Phase 2b (GH001-TRD-201, n=81) met primary endpoint Feb 2025: -15.5 MADRS vs placebo (p<0.0001), 57.7% remission vs 0%, 77.8% remission at 6-month OLE. Single-day dosing, no psychotherapy required, patients discharge-ready within 1 hour. FDA clinical hold lifted 2025. Phase 3 global initiation planned 2026.
GH001
5-MeO-DMTBipolar II disorder with a depressive episode. Inhaled mebufotenin. Phase 2 open-label trial completed; data included in regulatory package.
GH001
5-MeO-DMTPostpartum depression (PPD). Inhaled mebufotenin. Phase 2 open-label trial completed.
GH002
5-MeO-DMTTRD and other psychiatric indications. IV mebufotenin formulation. Phase 1 in 64 healthy volunteers completed Q4 2023; well-tolerated. Phase 2 planning stage.
Quick Facts
- Type
- Public Biotech
- Founded
- 2018
- Ticker
- NASDAQ: GHRS
- Lead Stage
- Phase III
- HQ
- 28 Baggot Street Lower, Dublin 2, Ireland, Ireland
- Website
- Visit